Introduction
Glucocorticoids (GCs) are released from the adrenal cortex and regulated by the hypothalamic-pituitary-adrenal axis. They are a class of steroid hormones and play an important role in the stress responses. They can readily cross the blood-brain barrier and participate in many of the central nervous system (CNS) functions by binding to mineralocorticoid and glucocorticoid receptors. While physiological levels of glucocorticoid facilitate long-term potentiation [1, 2] and enhance learning and memory [3] , too low or too high levels may cause impairment. In addition, stress or glucocorticoid levels may affect hippocampusdependent learning and synaptic plasticity, following the 'inverted U-shaped' curve [4] [5] [6] [7] .
Dexamethasone (Dex) is a synthetic glucocorticoidlike compound, and has been used to induce neuronal impairment in primary cultured cortical neurons and in vivo. well as a neuroprotective effect against glutamate-induced neuronal excitotoxicity [8] [9] [10] [11] [12] . To date, there is no report on the neuroprotective effect of Sch against Dex-induced CNS deficits. Therefore, the present study was designed to evaluate the neuroprotective effects of Sch against Dex exposure both in vitro and in vivo. and SYBR ® Premix Ex Taq™ kit were from Takara (Tokyo, Japan). Cell culture plates were from Jet Biofil (Canada). were assessed for viability. days). Dex and Sch were suspended in distilled water for administration. To avoid effects on the behavioral tests, the solutions were administered at 17:00 and the tests were performed the next day between 08:00 and 16:00.
Materials and methods

Materials and reagents
Cell culture and treatment
Animals and grouping
Cell survival assay
Cell viability was assessed using the MTT assay. After neurons were treated for 72 h, the medium was replaced by DMEM/F12 with MTT (10:1, v/v;
MTT was first prepared at 0.5 mg/mL in PBS). After incubation for 4 h, the medium was removed and DMSO (150 μL) was added to each well to dissolve the formazan.
Absorbance was measured at 570 nm using a Bio-Rad 400 microplate reader (Bio-Rad, Hercules, CA). All samples were tested in triplicate.
Morris water maze test
The maze (50 cm in height and 110 cm in diameter) was divided into four quadrants by four fixed points, and filled with water to a depth of 30 cm. The water temperature was maintained at 22-25ºC. An 8-cm diameter escape platform was kept in one quadrant of the pool and submerged 1 cm below the water surface. The platform had the same color as the tank and the water was rendered opaque with nontoxic ink. Mice were trained to find the hidden platform according to the spatial cues in the pool. Each mouse was placed gently at a start point in the middle of the rim of a quadrant, facing the wall, and was allowed 60 s to find the platform. After finding the platform, the mouse was allowed to stay on the platform for 15 s.
If the mouse failed to find the platform, it was manually guided to it and allowed to stay there for 15 s. Each mouse had two trials per day for 5 successive days (from day 23 to day 27, or from day 37 to day 41 of treatment). On day 6, 24 h after the previous trial, the platform was removed from the maze and mouse was allowed to swim for 60 s.
During the experiment, each mouse was monitored by a digital camera 80 cm above the maze and parameters were analyzed using the DigBehav 3.0 system (Jiliang Software Technology Co. Ltd., Shanghai, China). 
Histological analysis
Data analysis All data are expressed as mean ± SEM
and were analyzed by one-way analysis of variance (ANOVA)
followed by Bonferroni or LSD post hoc test. P <0.05 was considered statistically significant. against Dex-induced toxicity in a dose-dependent manner (Fig. 3, Table S1 ). Dex treatment for 28 days, the 15 and 45 mg/kg Sch-treated groups were improved (Fig. 5) . These results indicated that Sch significantly alleviates the cognitive impairment induced by Dex. 
Results
Neurotoxicity of Dex
Sch alleviated the cognitive impairment induced by Dex
Effects of
Discussion
Many studies in humans and animals have shown a close relationship between high GC levels and cognitive impairment, and Cushing's disease is associated with memory impairment [13, 14] . In clinical practice, prolonged GC therapy may influence cognition [15] [16] [17] , causing declarative memory impairment via cumulative and long-lasting detrimental influences on hippocampal function, including altered adrenal steroid receptor density, neurotransmitter content and dendritic atrophy [16, 18, 19] . Here, we found that Dex decreased neuronal viability and caused damage to neurites in vitro, as well as impairing spatial learning and memory in vivo. Our model can be used to screen for potential neuroprotective drugs against the neuronal impairment induced by GCs.
In vivo, it was reported that chronic (21 days) treatment with stress-levels of Dex induces learning and memory impairment in old male mice but not in young mice [20] . We also assessed the learning and memory in mice by the Morris water maze test after continuous treatment with Dex for 21 days, and obtained similar results (data not shown). So in our experiments, Dex administration in vivo was prolonged to 28 days, which successfully induced cognitive deficits in young KM mice.
Mice that received Dex for 28 days followed by vehicle for 14 days presented no significant differences in water maze performance, compared with mice receiving Dex for 42 days. These results suggested that the neuronal impairment induced by 28-day exposure to Dex was stable until the end of the experiment. This model thus provides a window of two weeks to assess the effects of potential drugs on cognition.
Chronic stress has been shown to alter the structure and function of the hippocampus [21] [22] [23] , and GC plays a central role in this process [24] . Stress and high GC levels cause reductions in hippocampal volume [25] [26] [27] . In addition, the hippocampus is not only a target for GCs but also a key structure for the feedback control of its secretion. Therefore, the death of hippocampal cells leads to failure of the feedback. This vicious cycle would lead to further neuronal loss. In the present study, we found morphological degeneration in the hippocampus from Dex-treated mice, which further confirmed that high levels of GCs cause severe brain damage.
Neuroprotective compounds with low molecular weight can readily cross the blood-brain barrier, and might have potential in the treatment of CNS disorders. In our studies, we screened neuroprotective compounds in Dexexposed cortical neurons, and found that Sch protected neurons against a high level of Dex. The results in vivo further confirmed that Sch improved the spatial learning and memory, and alleviate hippocampal degeneration in Dex-treated mice. This is the first report that Sch prevents
Dex-induced impairment in vivo and in vitro; however, the underlying mechanisms need to be further explored.
Supplemental Data: Supplemental Data include three tables and can be found online at http://www.neurosci.cn/ epData.asp?id=33.
